Pneumonia, Pneumococcal Therapeutic Market 規模およびシェア分析 - 成長トレンドおよび予測 (2024 - 2031)
Pneumonia, Pneumococcal Therapeutic Market is segmented By Route of Administration (Oral, Intravenous, Subcutaneous, Parenteral, Topical), By Molecule Type (Recombinant Fusion Proteins, Small Molecule, Monoclonal Antibody, Peptide Polymer, Gene Therapy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Competitive overview of Pneumonia, Pneumococcal Therapeutic Market
The major players operating in the Pneumonia, Pneumococcal Therapeutic Market include Biotest AG, Vaxcyte, Inc., Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc., Sanofi, Johnson & Johnson, Astellas Pharma Inc., CSL Limited, Mitsubishi Tanabe Pharma Corporation, Bavarian Nordic, and SutroVax, Inc.
Pneumonia, Pneumococcal Therapeutic Market Leaders
- Biotest AG
- Vaxcyte, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- GlaxoSmithKline plc.
Pneumonia, Pneumococcal Therapeutic Market - Competitive Rivalry, 2023
Pneumonia, Pneumococcal Therapeutic Market
(Dominated by major players)
(Highly competitive with lots of players.)